Brepocitinib for Lichen Planopilaris
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 342 (estimated)
- Sponsor
- Priovant Therapeutics, Inc. · Industry
This trial is looking for adults with a condition called lichen planopilaris. Participants will take an oral medication called brepocitinib to see how safe and effective it is for their symptoms.
You may be able to join if
- I am at least 18 years old
- I weigh more than 40 kg but less than 130 kg
- My body mass index (BMI) is 45 or less
- I have had a biopsy that confirms I have lichen planopilaris
- I have active and symptomatic lichen planopilaris
You may not be able to join if
- I have a history of a lymphoproliferative disorder
- I have an active cancer or had cancer in the last 5 years
- I am at high risk for blood clots or heart disease
- I am at high risk for shingles (herpes zoster)
- I have an active or recent infection
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
Loading trial locations…